FDA – Page 80 – Pharma.Tips

AE reporting non-compliance during signal review – how to strengthen benefit–risk documentation

Addressing AE Reporting Non-Compliance During Signal Review for Enhanced Benefit-Risk Documentation Adverse Event (AE) reporting non-compliance during signal review represents a critical concern for pharmaceutical organizations facing regulatory scrutiny. The…

Material specification drift during market launch – how to prevent recall triggers

Understanding the Challenges of Material Specification Drift During Market Launch and Prevention Strategies In the fast-paced world of pharmaceutical production, material specification drift during market launch raises significant concerns that…

Periodic report inconsistencies during post-marketing surveillance – inspection questioning scenarios

Addressing Anomalies in Periodic Reports During Post-Marketing Surveillance Periodic report inconsistencies during post-marketing surveillance can pose significant challenges for pharmaceutical companies. These discrepancies, if left unaddressed, may not only lead…

Material specification drift during development – inspection evidence expectations

Understanding Material Specification Drift During Development: Evidence Expectations for Inspections Material specification drift during development can significantly impact the quality and consistency of pharmaceutical products. This phenomenon may lead to…

Periodic report inconsistencies during audit response – regulatory enforcement risk and mitigation

Addressing Inconsistencies in Periodic Reports During Audit Responses In the pharmaceutical industry, maintaining consistent and accurate periodic reports is crucial, especially during regulatory audits that are inherent to compliance with…

Material specification drift during scale-up – inspection evidence expectations

Understanding and Investigating Material Specification Drift During Scale-Up Material specification drift during scale-up can create significant challenges within pharmaceutical manufacturing, impacting product quality and regulatory compliance. As organizations strive for…

Case processing backlog during benefit–risk assessment – how to strengthen benefit–risk documentation

“`html Addressing Challenges of Case Processing Backlogs in Benefit–Risk Assessments The growing complexity of clinical data management and regulatory scrutiny has resulted in significant case processing backlogs during benefit–risk assessments.…

Stability impact underestimated during scale-up – CAPA and control strategy

Addressing Underestimated Stability Impact During Scale-Up: A Comprehensive Investigation The transition from lab-scale to commercial-scale production is often fraught with challenges, especially when the stability of a product is underestimated.…

Risk management plan gaps during inspection – regulatory enforcement risk and mitigation

Identifying and Addressing Risk Management Plan Gaps During Regulatory Inspections In the pharmaceutical industry, the integrity of risk management plans is paramount, especially in the face of regulatory inspections. Gaps…

Container closure integrity risk during supplier change – regulatory risk analysis and mitigation

Analyzing Risks in Container Closure Integrity During Supplier Transitions In the competitive landscape of pharmaceutical packaging, a change in suppliers can pose significant risks to container closure integrity (CCI). This…

PV system audit finding during benefit–risk assessment – regulatory enforcement risk and mitigation

Addressing PV System Audit Findings in Benefit–Risk Assessments: An Investigation Framework Pharmaceutical companies face a critical challenge when managing audit findings related to pharmacovigilance (PV) systems during benefit-risk assessments. Non-compliance…

Packaging compatibility risk during supplier change – documentation gaps regulators question

Investigating Packaging Compatibility Risks During Supplier Changes: Ensuring Compliance and Readiness In the pharmaceutical industry, the transition to a new supplier poses significant risks, particularly concerning packaging compatibility. If not…